Coronary Blood Flow Regulation During General Anesthesia

October 12, 2015 updated by: C.S.E. Bulte, Amsterdam UMC, location VUmc

Cardiac Sympathetic Innervation and Coronary Blood Flow Regulation During General Anesthesia

The central hypothesis in the present project is that general anesthesia may alter autonomic control such that perioperative coronary blood flow (CBF) is significantly disturbed.

These disturbances in coronary blood flow may contribute to the development of myocardial ischemia in the perioperative period. Furthermore, patients with an intrinsically altered autonomic sympathetic innervation, like diabetics, are even more prone to develop perioperative disturbances in coronary blood flow.

Here the researchers will investigate what the direct effects are of general and locoregional anesthesia on the CBF. Furthermore, the researchers aim to evaluate whether diabetic subjects show more disturbed CBF responses to anesthesia as compared to non-diabetics.

Study Overview

Detailed Description

In response to intraoperative stress, increased autonomic sympathetic activity may alter myocardial oxygen demand. Under normal physiological circumstances, sympathetic stimulation increases myocardial blood flow via adrenergic coronary vasodilation. However, coronary vessels contain both α- and β-adrenoreceptors, and if the coronary circulation is impaired due to cardiovascular disease, unopposed adrenergic coronary vasoconstriction may contribute to ischemia. Anesthetics reduce both coronary blood flow (CBF) regulation and the sympathetic autonomic nervous activity. However, it is unclear whether anesthetic-related reductions in CBF are a result of inhibited autonomic sympathetic innervation. Data regarding alterations in myocardial blood flow in response to sympathetic stimulation during anesthesia provide conflicting results. Moffitt and Sethna showed in patients undergoing cardiac surgery that CBF decreased during sternotomy-induced sympathetic stimulation, whereas Kirno et al. showed an increase in coronary blood flow after sternotomy. To our best knowledge, coronary vascular responses to sympathetic stimulation in anesthetized healthy humans are lacking because of absence of reliable non-invasive measurement of myocardial blood flow. The introduction of non-invasive contrast-echocardiographic techniques that allow evaluation of regional myocardial blood flow enable evaluation of the relation between autonomic control and CBF during anesthesia.

Cardiac complications like myocardial ischemia remain one of the main causes of perioperative morbidity and mortality. Interestingly, the presence of cardiovascular autonomic neuropathy (CAN) strongly predicts abnormalities in myocardial perfusion and impaired coronary vasodilator responses to stress. This implies that symptoms of CAN, like resting tachycardia, orthostasis and alterations in heart rate variability may predict the degree of impairment of CBF regulation. Indeed, autonomic neuropathy as determined by heart rate variability predicted mortality in patients with coronary artery disease undergoing non-cardiac surgery, but the contribution of impaired coronary vasodilatory responses to these results has not been established. Clarification of the relation between autonomic control and CBF during anesthesia may not only contribute to our insight in pro-ischemic processes in the heart, but may lead to changes in preoperative assessment of patients at risk for perioperative ischemia, thereby reducing perioperative complications.

Study Type

Observational

Enrollment (Actual)

45

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Noord-Holland
      • Amsterdam, Noord-Holland, Netherlands, 1007 MB
        • VU University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Sampling Method

Probability Sample

Study Population

The study population consists patients scheduled for surgery and general anesthesia. Patients will be recruited from the preoperative screening clinic in the four, aforementioned, groups of patients.

Description

Inclusion Criteria:

  • male
  • age between 18-75 years
  • scheduled for non-cardiac intermediate or high risk surgery
  • for patient group 2: indication for thoracic epidural anesthesia

Exclusion Criteria:

  • neurosurgery
  • known/documented cardiac disease
  • (untreated) hypertension
  • abnormal ECG or echocardiogram
  • peripheral vascular disease
  • renal disease requiring hemo- or peritoneal dialysis
  • inability to perform transthoracic echocardiography
  • medication interfering with presynaptic catecholamine uptake
  • for patient group 2: contra-indication for thoracic epidural anesthesia (bleeding diathesis, infection at the puncture site, patient refusal, severe stenotic valvular disease)
  • previous allergic reaction to echocardiographic contrast agents
  • contraindications for the use of echocardiographic contrast agents

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Healthy
Healthy subjects scheduled for general anesthesia
Healthy with thoracic epidural anelgesia
Healthy subjects scheduled for general anesthesia and thoracic epidural analgesia
Diabetes
Subjects with diabetes scheduled for general anesthesia
Diabetes with autonomic neuropathy
Subjects with diabetes and cardiovascular autonomic neuropathy scheduled for general anesthesia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Coronary flow reserve
Time Frame: Within the first 3 days postoperatively
Within the first 3 days postoperatively

Secondary Outcome Measures

Outcome Measure
Time Frame
Diabetic autonomic neuropathy
Time Frame: Within the first 3 days postoperatively
Within the first 3 days postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Carolien SE Bulte, MD, Amsterdam UMC, location VUmc
  • Principal Investigator: R. A. Bouwman, MD, PhD, Amsterdam UMC, location VUmc
  • Study Chair: C. Boer, PhD, Amsterdam UMC, location VUmc
  • Study Director: S. A. Loer, MD, PhD, MSC, Amsterdam UMC, location VUmc
  • Study Chair: O. Kamp, MD, PhD, Amsterdam UMC, location VUmc
  • Study Chair: M. Diamant, MD, PhD, Amsterdam UMC, location VUmc

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2009

Primary Completion (ACTUAL)

February 1, 2014

Study Completion (ACTUAL)

October 1, 2014

Study Registration Dates

First Submitted

March 20, 2009

First Submitted That Met QC Criteria

March 20, 2009

First Posted (ESTIMATE)

March 23, 2009

Study Record Updates

Last Update Posted (ESTIMATE)

October 14, 2015

Last Update Submitted That Met QC Criteria

October 12, 2015

Last Verified

October 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Ischemia

3
Subscribe